Clinical trials: Toripalimab
Colorectal Cancer Metastatic
A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
This is a phase I, open-label clinical study of T3011 in combination with Toraplizumab and Regorafenib in patients with liver metastases from colorectal cancer.
- Trial name
- NCT06283303
- Testing
- T3011 hepatic artery infusion, toripalimab, regorafenib
- Volunteers
- 8 people
- Sponsor
- China Medical University, China
Nasopharyngeal Carcinoma
Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients
This is a randomized Phase II trial to study the effectiveness and toxicity of neoadjuvant and adjuvant PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy versus cisplatin concurrent chemoradiotherapy…
- Trial name
- NCT03925090
- Testing
- Cisplatin+Toripalimab
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Sun Yat-sen University
Triple Negative Breast Cancer
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
This trial is an open-label, multicenter phase Ib/II clinical study to evaluate the efficacy and safety of LBL-024 monotherapy or in combination with albumin-bound paclitaxel in patients with recurrent or metastatic triple…
- Trial name
- NCT07281976
- Testing
- LBL-024 for Injection, albumin-bound Paclitaxel injection, Toripalimab Injection
- Where
- 7 sites in China
- Volunteers
- 220 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Breast Cancer
Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer
This is a mono-center, open-label, phase 1 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with triple negative breast cancer who have failed in routine systemic treatment.
- Trial name
- NCT02838823
- Testing
- humanized anti-PD-1 monoclonal antibody toripalimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Stage IIA-IIIB NSCLC, Selective Mediastinal Lymph Node Sampling
Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer (SCIENCE Study)
The SCIENCE trial is a multicenter, open-label, randomized, parallel, noninferiority investigator-initiated trial (IIT). This study aims to evaluate the prognostic differences between selective mediastinal lymph node sampling and…
- Conditions
- Stage IIA-IIIB NSCLC, Selective Mediastinal Lymph Node Sampling, Systematic medIastinal Lymph Node Dissection
- Trial name
- NCT07617389
- Testing
- selective mediastinal lymph node sampling, systematic mediastinal lymph node dissection
- Where
- China
- Volunteers
- 358 people
- Sponsor
- Wen-zhao ZHONG
Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
Research purposes: the research design in the late more than 2 lines TNBC prospective, multicenter, cohort study, respectively to observe Trop2 - ADC joint PD - 1 single or combined anti-angiogenesis drugs (macromolecular single…
- Trial name
- NCT06878625
- Testing
- Sacituzumab Govitecan combined with Toripalimab, Sacituzumab govitecan combined with anti-angiogenesis
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Nasopharyngeal Carcinoma (NPC)
Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma
Immunotherapy combined with chemoradiotherapy has become standard care for locally advanced nasopharyngeal carcinoma, yet radiotherapy-induced lymphopenia may impair the efficacy of concurrent PD-1 blockade.
- Trial name
- NCT07706985
- Testing
- Toripalimab combined with Nimotuzumab, Nimotuzumab
- Where
- China
- Volunteers
- 566 people
- Sponsor
- Sun Yat-sen University
Advanced Biliary Tract Tumors
Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX Regimen
This is an open, single-arm, single-center, prospective phase II clinical study to evaluate the efficacy and safety of first-line tripletrumab combined with GEMOX chemotherapy in patients with advanced biliary tract tumors.
- Trial name
- NCT04191343
- Testing
- Toripalimab injection combined with GEMOX
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Metastatic Colorectal Adenocarcinoma
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Fruquintinib with PD-1 inhibitors (FP) and TAS-102 with bevacizumab (TB) are two common therapies for patients with previous-treated metastatic colorectal cancer (mCRC).
- Trial name
- NCT06031376
- Testing
- Fruquintinib, PD-1 inhibitors, Trifluridine/Tipiracil
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Hunan Cancer Hospital
Advanced Lung Cancer
A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer
This is a multicenter, open-label Phase II clinical study, with the main objective being to evaluate the investigator-assessed objective response rate of JS212 in combination therapy for advanced lung cancer.
- Trial name
- NCT07309276
- Testing
- JS212 for Injection, JS207 for Injection, Toripalimab
- Where
- China
- Volunteers
- 864 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Advanced Solid Tumor
Study on the Treatment of Advanced Malignant Solid Tumor With Revottack and PD-1 Inhibitor
This is a one arm, open clinical pharmacological exploration study initiated by researchers to evaluate the safety and effectiveness of vesicular stomatitis oncolytic virus injection (Revottack) combined with PD-1 inhibitor in…
- Trial name
- NCT05644509
- Testing
- Oncolytic Virus Injection（Revottack）+PD-1
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Non Squamous Non Small Cell Lung Cancer, EGFR Positive Non-small Cell Lung Cancer
Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation
This study was designed to investigate the efficacy and safety of neoadjuvant Toripalimab (anti-PD1) plus chemotherapy for patients with resectable II-IIIB non-squamous NSCLC harboring EGFR mutation, and to explore the potential…
- Trial name
- NCT05962021
- Testing
- Toripalimab plus Chemotherapy
- Volunteers
- 126 people
- Sponsor
- Peking University People's Hospital
Head and Neck Cancer
A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy
Head and neck cancer is the malignant tumor with the highest morbidity and mortality, of which 60% present with locally advanced disease at initial diagnosis, and the 5-year survival rate of standard treatment is less than 30%.
- Trial name
- NCT06208826
- Testing
- Toripalimab, Radiation Therapy, Cisplatin
- Where
- China
- Volunteers
- 268 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Malignant Lymphoma
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma
The primary objective is to assess the safety and tolerability of JS-001 in subjects with recurrent malignant lymphoma, and to evaluate its preliminary efficacy.
- Trial name
- NCT03316144
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Malignant Pleural Mesothelioma
Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma
This is a single-arm, open, II phase study to evaluate the safety and efficacy of Toripalimab, pemetrexed and carboplatin in the treatment of locally advanced malignant MPM in 15 newly diagnosed patients with locally advanced…
- Trial name
- NCT04713761
- Testing
- Toripalimab
- Volunteers
- 15 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Locally Advanced Head and Neck Squamous Cell Carcinoma
Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma
The guidelines for locally advanced head and neck squamous cell carcinoma currently recommend surgery / radiotherapy / chemotherapy / targeted therapy.
- Trial name
- NCT05773079
- Testing
- Toripalimab
- Volunteers
- 28 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Nasopharyngeal Cancinoma (NPC)
GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) has a low incidence rate in children, accounting for only 1-2% of pediatric tumors. However, it is prone to metastasis, and most patients are already in advanced stages at the time of diagnosis.
- Trial name
- NCT06605131
- Testing
- GP+Toripalimab+CCRT, GP+CCRT
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Sun Yat-sen University
Early Low Rectal Cancer
The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer
The study evaluates the combination of immunotherapy of PD-1 antibody and neoadjuvant short-course radiotherapy in early low rectal cancer.
- Trial name
- TORCH-E (NCT05555888)
- Testing
- PD-1 antibody, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Fudan University
NSCLC, NSCLC (Non-small Cell Lung Cancer)
Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial
The primary objective of this study is to evaluate whether neoadjuvant SBRT as an immunomodulator in combination with apalolimab and toripalimab (QL1706) plus chemotherapy improves the pathological complete response (pCR) rate in…
- Trial name
- NCT07286942
- Testing
- apalolimab and toripalimab (QL1706)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Hepatocellular Carcinoma
Phase II of Lenvatinib Plus Toripalimab for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with toripalimab in patients with advanced hepatocellular carcinoma (HCC)
- Trial name
- NCT03919383
- Testing
- Lenvatinib, Toripalimab
- Where
- China
- Sponsor
- Sun Yat-sen University